Loomis, Sayles & Company
SLXP

Loomis, Sayles & Company’s SALIX PHARMACEUTICALS LTD DEL SLXP Stock Holding History

Loomis, Sayles & Company’s Portfolio SLXP Stock Details SLXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-486
Closed -$76K – 784
2014
Q3 		$76K Sell
486
-180
-27% -$26.1K ﹤0.01% 679
2014
Q2 		$82K Sell
666
-10
-1% -$1.1K ﹤0.01% 707
2014
Q1 		$70K Buy
676
+428
+173% +$43.8K ﹤0.01% 696
2013
Q4 		$22K Buy
248
+23
+10% +$1.83K ﹤0.01% 731
2013
Q3 		$15K Hold
225
– – ﹤0.01% 729
2013
Q2 		$15 Buy
+225
New +$12.9K ﹤0.01% 712

Other funds holding SLXP

PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Loomis, Sayles & Company's SLXP Position: Q4 2014 in Review

Loomis, Sayles & Company sold out of SALIX PHARMACEUTICALS LTD DEL (SLXP) in Q4 2014, closing a stake of 486 shares — an estimated $76K sold.

Loomis, Sayles & Company first reported a position in SLXP in Q2 2013 and held it in 6 quarters. The position peaked at $82K in Q2 2014. 346 funds tracked by Wall St. Rank hold SLXP as of Q4 2014.

  • Loomis, Sayles & Company reported no remaining SALIX PHARMACEUTICALS LTD DEL position as of Q4 2014 after selling out during the quarter.
  • Loomis, Sayles & Company sold 486 SALIX PHARMACEUTICALS LTD DEL shares in Q4 2014, an estimated $76K.
  • Loomis, Sayles & Company first reported a position in SALIX PHARMACEUTICALS LTD DEL in Q2 2013 and held it in 6 quarters.
  • Loomis, Sayles & Company's SALIX PHARMACEUTICALS LTD DEL position peaked at $82K in Q2 2014.
  • 346 funds tracked by Wall St. Rank held SALIX PHARMACEUTICALS LTD DEL as of Q4 2014.

Based on Loomis, Sayles & Company's 13F filing for Q4 2014, filed 17 Feb 2015.